• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>The Second Asian symposium on pharmaceutical sciences and technology >Double-targeted Nanostructured Lipid Carriers with Anti-VEGFR-2 Antibody for Tumor Specific Therapy
【24h】

Double-targeted Nanostructured Lipid Carriers with Anti-VEGFR-2 Antibody for Tumor Specific Therapy

机译：具有抗VEGFR-2抗体的双靶纳米结构脂质载体用于肿瘤特异性治疗

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: This study aimed to develop and evaluate a "one-double targeting" drug delivery system. Methods: Flk-l(A-3), a mouse monoclonal anti-VEGFR-2 antibody, modified docetaxel (DTX)-loaded targeted nanostructured lipid carriers (tNLC) has been constructed. The cellular cytotoxicity, uptake, in vivo therapeutic effect and biodistribution were investigated. Results: The tNLC showed better tolerant and antitumor efficacy in murine model bearing B16 compared with Duopafei?or nNLC. The results of cellular uptake and biodistribution studies indicated the better antitumor efficacy of tNLC was attributed to both the increased accumulation of drug in tumor and tumor vasculature. Conclusion: The double-targeted NLC with anti-VEGFR-2 antibody could efficiently deliver DTX to the targeted tumor vasculature and tumor site.
机译：目的：本研究旨在开发和评估“双重靶向”药物输送系统。方法：构建了小鼠单克隆抗VEGFR-2抗体Flk-1（A-3），修饰的多西他赛（DTX）加载的靶向纳米结构脂质载体（tNLC）。研究了细胞的细胞毒性，摄取，体内治疗作用和生物分布。结果：与Duopafei？或nNLC相比，tNLC在带有B16的鼠模型中显示出更好的耐受性和抗肿瘤功效。细胞摄取和生物分布研究的结果表明，tNLC更好的抗肿瘤功效归因于药物在肿瘤和肿瘤脉管系统中的积累增加。结论：抗VEGFR-2抗体的双重靶向NLC可以有效地将DTX递送至靶向的肿瘤血管和肿瘤部位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号